Our news journalists obtained a quote from the research from Fukushima Medical University, "Thirty patients with relapsed/refractory/poor-risk non-Hodgkin lymphoma (NHL n = 27) or Hodgkin lymphoma (HD n = 3) were uniformly treated with an MCVC regimen and underwent auto-SCT. The median follow-up duration of the surviving patients was 67 months (56-133 months). The major toxicities were anorexia (94 %), diarrhea (80 %), nausea (79 %), febrile neutropenia (70 %), alopecia (67 %) and mucositis (60 %). Three patients developed severe left ventricular dysfunction, and two patients developed severe sinusoidal obstructive syndrome (SOS). Of these patients, two died without disease progression. Treatment-related mortality was 6.6 %. Late-onset adverse events including two cases of cytomegalovirus pneumonia and one of interstitial pneumonia were observed. In DLBCL (n = 13) and transformed FL (n = 2) patients, OS and EFS at 3 years were 72 and 46 %, respectively. These results suggest that the MCVC regimen followed by auto-SCT is a feasible and tolerable therapy for relapsed/refractory malignant lymphoma. However, cardiac toxicity due to high-dose cyclophosphamide and development of SOS can occur and should be carefully monitored."
According to the news editors, the research concluded: "Further follow-up is needed to evaluate the long-term efficacy and safety of this regimen."
For more information on this research see: Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma. International Journal of Hematology, 2012;96(5):624-630. International Journal of Hematology can be contacted at: Springer Japan Kk, Chiyoda First Bldg East, 3-8-1 Nishi-Kanda, Chiyoda-Ku, Tokyo, 101-0065, Japan. (Springer - www.springer.com; International Journal of Hematology - www.springerlink.com/content/0925-5710/)
The news correspondents report that additional information may be obtained from Y. Kameoka, Fukushima Med Univ, Dept. of Cardiol & Hematol, Fukushima, Japan.
Keywords for this news article include: Asia, Antineoplastics, Pharmaceuticals, Japan, Drugs, Therapy, Lymphoma, Oncology, Fukushima, Carboplatin, Hydrocarbons, Cyclophosphamide, Alkylating Agents, Mustard Compounds, Lymphatic Diseases, Stem Cell Research, Hematology Research, Phosphoramide Mustards, Organoplatinum Compounds, Immunoproliferative Disorders
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.